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knowledge through an international network to overcome shortage
of information from own region (WHO Traditional Medicine
Strategy, 2002–2005, 2002). We believe that multiple reference
sources, especially those published from countries where herbal
medicine is more commonly used, should be used in order to
provide an evidence-based advice.
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Sir,
Drug information services such as the Chinese Medicine
Advisory Service at the Medical Toxicology Unit at Guy’s and St
Thomas’ Hospital Trust make an important contribution to the
safety management of patients taking complementary alternative
medicines (CAMs). We are aware that these services exist and
increased resort to the service they offer is needed. Our proposal is
that doctors will need to devote time to discussing CAM use in
outpatient clinics although the complexities of side effects and
interactions may require clinics which are run jointly with a local
medicines information and toxicology services (Werneke et al,
2004). Such work may not be feasible in routine outpatient clinics
where patients may be seen only briefly. Joint clinics would not
only address drug safety concerns but also the patients’ motivation
for opting for CAMs, for instance to gain a greater degree of
control over their illness and its treatment, and thereby to regain
control over their lives (Sparber et al, 2000).
We agree with Shia et al that herbal remedies may have
beneficial synergistic effects with conventional therapies. How-
ever, patients may take CAMs for a variety of reasons
including reduction of cytotoxicity and its associated side
effects rather than increasing it. This is highlighted by an e-
mail we received in response to out study from a naturopath
who asserted:’ yyou will find that more people die of the
chemotherapy than the cancer itself. Therefore if the herbs are
making the chemo less effective this could be a beneficial
thingy’. Thus, there is a need to work out and implement an
individualised treatment plan for each patient wishing to use
CAMs, and this may be beyond the scope of a drug
information service.
Shia et al suggest prospective studies to evaluate the
interactions between conventional and complementary medicines.
However, such studies may be difficult to conduct if there are
reasons to suspect potentially serious interactions or a significant
reduction in efficacy of the conventional treatment, which could
lead to a reduction in survival time. It may not be ethically
acceptable to opt for ‘watchful waiting’ in such cases, and one
may wish to err on the side of caution. In view of this, we
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for adverse effects in others. Prospective studies could be further
complicated by the fact that many patients take combinations of
remedies rather than one substance only, which may not always
make it possible to attribute an adverse reaction unambiguously
to one agent.
In consequence, we feel that the research on and management of
CAMs should be integrated into the conventional cancer care to
provide a truly holistic approach and to enable clinicians to adapt
CAMs and conventional therapies to patients’ individual require-
ments and to take account of changes in the clinical course
whenever they occur.
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